Suven to present data on SUVN 502 at UK conference

Subscribe to Oneindia News

Hyderabad, Oct 13 (UNI) Suven Life Sciences, a biopharmaceutical company, today announced it would present data on Phase I clinical trial candidate SUVN 502 for cognition in Alzheimer's and Schizophrenia at the '16th Annual Bio Partnering Europe' meet tomorrow.

Besides, Suven Life Sciences CEO Venkat Jasti will discuss company's business strategy and corporate overview at the QE11 Conference Centre at London.

The company has six internally discovered therapeutic drug candidates currently in clinical and pre-clinical stage of development targeting conditions such as ADHD, dementia and depression, Parkinson's disease, a press release here said.

UNI VA GM 1451

Please Wait while comments are loading...